Selank and semax for depression and anxiety: hype vs. evidence
Quick answer
Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition. The dosing figures cited in the video appear drawn from Russian clinical literature and informal community use, not from standardized pharmacokinetic or dose-finding trials in U.S. or EU populations. Anyone with a clinical diagnosis of anxiety or depression should consult a licensed provider before considering either compound, as drug interactions, contraindications, and quality control risks remain poorly characterized outside controlled research settings.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @daviddemesquita actually say?
The creator recommended two peptides, which he calls "C-Max" (semax) and "Slank" (selank), for anxiety and depression. He described semax as helping with "sense of urgency" and cognitive focus, citing use in stroke patients, and selank as a "calming agent" for anxiety. He suggested doses of 500 micrograms for semax, taken two to three times daily, and 400 micrograms of selank twice daily, with a 30-minute separation between the two. He used stroke dosing of up to 5 milligrams per day as evidence of both efficacy and safety.
To be clear about the names: these peptides are semax and selank, not "C-Max" and "Slank." The mispronunciation matters because people searching for these compounds need accurate terminology. The creator's general framing, that these are distinct peptides with opposite functional profiles, is roughly consistent with their pharmacological research backgrounds.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Selank and semax for depression and anxiety: hype vs. evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Selank and semax for depression and anxiety: hype vs. evidence is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition.
FormBlends verdict
Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition. The dosing figures cited in the video appear drawn from Russian clinical literature and informal community use, not from standardized pharmacokinetic or dose-finding trials in U.S. or EU populations. Anyone with a clinical diagnosis of anxiety or depression should consult a licensed provider before considering either compound, as drug interactions, contraindications, and quality control risks remain poorly characterized outside controlled research settings.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semax and selank are synthetic peptides developed in Russia with preliminary evidence supporting nootropic and anxiolytic effects respectively, but neither has been reviewed or approved by the FDA for any condition. The dosing figures cited in the video appear drawn from Russian clinical literature and informal community use, not from standardized pharmacokinetic or dose-finding trials in U.S. or EU populations. Anyone with a clinical diagnosis of anxiety or depression should consult a licensed provider before considering either compound, as drug interactions, contraindications, and quality control risks remain poorly characterized outside controlled research settings.
- Neither semax nor selank is FDA-approved for any condition, including depression, anxiety, or cognitive enhancement. Both are research compounds in the United States.
- Semax is registered as a drug in Russia for stroke and cognitive impairment. Gusev et al. (1997) supports its use in ischemic stroke recovery, which is the one claim the creator made that has genuine published backing.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Neither semax nor selank is FDA-approved for any condition, including depression, anxiety, or cognitive enhancement. Both are research compounds in the United States.
- Semax is registered as a drug in Russia for stroke and cognitive impairment. Gusev et al. (1997) supports its use in ischemic stroke recovery, which is the one claim the creator made that has genuine published backing.
- Selank's anxiolytic effects are supported by limited human trials, including Semenova et al. (2010), but those trials involved small samples and were conducted in Russian clinical settings, limiting generalizability.
- The argument that high doses used in stroke patients prove general safety is logically flawed. Therapeutic context, monitoring, and patient population all affect what a dose tells us about risk.
- Route of administration matters. Intranasal and subcutaneous semax dosing produce different bioavailability profiles, and the video does not specify route, which makes the dose figures difficult to evaluate.
- Compounded or research-chemical versions of these peptides carry real purity and concentration risks. No regulatory body has verified the quality of products sold outside a licensed pharmacy framework.
- If you have a diagnosed mood disorder or are on psychiatric medications, consult a licensed clinician before using either peptide. Interaction data with antidepressants or anxiolytics is essentially nonexistent in published literature.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
David DeMesquita™️ · TikTok creator
66.6K views on this video
Replying to @Justin Bushovisky #depression #anxiety #bodybuilding #peptide
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by David DeMesquita™️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.